Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276

CNE0000014W7

Pharmaceuticals

End-of-day quote Shanghai S.E. Other stock markets 2026-02-11			5-day change	1st Jan Change
58.90 ^CNY	+0.86%		+2.26%	-1.12%

Feb. 11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT
Feb. 10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE

Tranche Update on Jiangsu Hengrui Pharmaceuticals Co.,Ltd's Equity Buyback Plan announced on August 20, 2025.

Published on 01/04/2026 at 03:55 am EST

S&P Capital IQ

JIANGSU HENGRUI PHARMACEUTICALS CO.,LTD

+0.86%

From October 1, 2025 to December 31, 2025, the company has repurchased 4,326,300 shares, representing 0.06% for CNY 279.81 million. With this, the company has completed the repurchase of 8,898,700 shares, representing 0.14% for CNY 595.22 million under the buyback announced on August 20, 2025.

Latest news about Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Feb. 11	Jiangsu Hengrui Medicine Gets Priority Review Approval for Colorectal Cancer Drug	MT
Feb. 10	Kailera Therapeutics & Hengrui Pharma report positive topline data from phase 2 obesity trial of oral ribupatide	RE
Feb. 10	Kailera, Hengrui's experimental pill shows 12.1% weight loss in mid-stage trial	RE
Feb. 10	Kailera Therapeutics and Hengrui Pharma Report Positive Topline Data from Phase 2 Obesity Trial of Oral Ribupatide	CI
Feb. 08	Jiangsu Hengrui Medicine Gets Breakthrough Therapy Designation for Cancer Drug	MT
Feb. 05	Hengrui Pharmaceuticals' Gout Drug Application Accepted by Regulators	MT
Jan. 28	China Designates Jiangsu Hengrui Medicine's Lipid Disease Tablet as Breakthrough Therapy	MT
Jan. 27	Hengrui Pharma Gets Nod for Solid Tumor Injection's Clinical Trials	MT
Jan. 22	Hengrui Pharmaceuticals' Subsidiaries Get Nod to Trial Two Tumor Drugs	MT
Jan. 20	Hengrui Pharmaceuticals' Unit Gets Nod to Trial Diabetes Drugs	MT
Jan. 20	Hengrui Pharmaceuticals Gets Nod to Trial Two Tumor Drugs	MT
Jan. 20	Citigroup's long position in H shares of Jiangsu Hengrui Pharmaceuticals increases to 5.21% on Jan 14 - HKEX	RE
Jan. 12	Hengrui Pharma Unit Secures Approval to Conduct Clinical Trial for Hypertension Drug	MT
Jan. 12	Hengrui Pharma's Cancer Drug Obtains China Breakthrough Therapy Designation	MT
Jan. 07	Hengrui Pharmaceuticals Wins China Marketing Approval for Gastric Cancer Drug	MT
Jan. 07	Jiangsu Hengrui Pharmaceuticals says unit got notice from NMPA for retlirafusp alfa injection	RE
Jan. 05	Hengrui Pharmaceuticals Gets Regulatory Nod for Prostate Cancer Clinical Trials	MT
Jan. 05	Hengrui Pharmaceuticals Gets Approval for Combined Obesity Drug Trials	MT
Jan. 04	HUTCHMED Begins Phase 3 Trial of Surufatinib and Camrelizumab to Treat Pancreatic Cancer	MT
Jan. 04	Tranche Update on Jiangsu Hengrui Pharmaceuticals Co.,Ltd's Equity Buyback Plan announced on August 20, 2025.	CI
Dec. 30	Hengrui Pharma Gets Nod to Trial Six Drugs	MT
Dec. 30	Hengrui Pharma Gets Nod to Trial HRS-6257 Tablets	MT
Dec. 28	Hengrui Pharmaceuticals Licenses Kidney Drug to Hansoh Pharma in Related-Party Deal	MT
Dec. 28	Jiangsu Hengrui Pharmaceuticals Co.,Ltd Enters into A License Agreement	CI
Dec. 21	Jiangsu Hengrui Pharmaceuticals Co.,Ltd(SEHK:1276) added to S&P Global BMI Index	CI

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

Duration

Period

Chart Jiangsu Hengrui Pharmaceuticals Co.,Ltd

600276: Dynamic Chart

Company Profile

Jiangsu Hengrui Medicine Co., Ltd. specializes in the research, development, manufacture and marketing of pharmaceutical products. The activity is organized primarily around 5 families of products: - anti-tumor drugs (No. 1 Chinese); - Anesthetic drugs; - contrast agents: used in medical imaging; - anti-inflammatory drugs; - drugs for the treatment of cardiovascular diseases.

Employees

20,238

Sector

Pharmaceuticals

Calendar

Mar. 25 - Q4 2025 Earnings Release

More about the company